Immunovant, Inc. (NASDAQ: IMVT) disclosed that its Chief Legal Officer, Christopher Van Tuyl, sold 2,877 shares of common stock on March 18, 2026. The shares were sold at $24.97 apiece, producing a total proceeds figure of $71,838.
The filing indicates the disposal was carried out to cover tax withholding obligations tied to the vesting and settlement of restricted stock units (RSUs). After the sale, Van Tuyl is reported to directly hold 147,053 shares of Immunovant common stock.
At the time of reporting, Immunovant's share price stood at $22.99, below the price achieved in Van Tuyl's transaction but still approximately 60% higher than the company’s share price six months earlier. Separately, InvestingPro's analysis notes the stock currently appears slightly overvalued relative to its Fair Value estimate and offers additional analytical resources, including seven ProTips and financial health scoring for IMVT.
Other corporate developments reported alongside the insider transaction include Immunovant's third-quarter 2026 results, where the company posted earnings per share of -0.61. That figure exceeded the consensus expectation of -0.72, a performance that market participants received positively.
On the analyst front, Bernstein SocGen Group initiated coverage of Immunovant with a neutral rating and a $28.00 price target. In its initial assessment, the firm assigned a non-risk-adjusted value of $2.4 billion to Immunovant’s Graves’ disease program, pairing that valuation with an 80% probability of success. The Sjogren’s syndrome program was valued at $2.0 billion with an assessed 70% probability of success.
These disclosures - the insider sale to satisfy RSU-related tax obligations, the quarterly earnings outperformance, and the new analyst coverage with program-level valuations - combine to present a concise snapshot of recent activity around Immunovant. The regulatory filing details the exact share count and price for the insider sale, while the company’s reported results and the analyst initiation provide context on financial performance and pipeline valuation assumptions.
Readers should note that valuation commentary reflecting InvestingPro's Fair Value view and Bernstein SocGen Group’s program valuations were included in the disclosures; where information is limited or presented as estimates by those providers, the record reflects those stated assessments rather than independent verification.